Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3345/kjp.2018.61.2.37 http://scihub22266oqcxt.onion/10.3345/kjp.2018.61.2.37 C5854840!5854840!29563942     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Korean+J+Pediatr 2018 ; 61 (2): 37-42 Nephropedia Template TP {{tp|p=29563942|t=2018. Atypical hemolytic uremic syndrome and eculizumab therapy in children |pdf=|usr=}}{{29563942}} gab.com Text Atypical hemolytic uremic syndrome and eculizumab therapy in children JO: Korean J Pediatr http://www.kidney.de/pget.php?&tw=1&pmid=29563942 #FOAvip Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating disorder that progressively damages systemic organs, resulting in stroke, end-stage renal disease, and death. The traditional treatment for aHUS is mainly plasmapheresis or plasma infusion; however, many children with aHUS will progress to chronic kidney disease despite plasma therapy. Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Currently, several guidelines for aHUS, including the Korean guideline, recommend eculizumab as the first-line therapy in children with aHUS. Moreover, life-long eculizumab therapy is generally recommended. Further studies on discontinuation of eculizumab are needed. Twit Text FOAVip Atypical hemolytic uremic syndrome and eculizumab therapy in children ????Korean J Pediatr http://www.kidney.de/pget.php?&tw=1&pmid=29563942 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29563942 #FOAvip English Wikipedia <ref>{{Cite pmid|29563942}}</ref> Atypical hemolytic uremic syndrome and eculizumab therapy in children #MMPMID29563942 Kim SH; Kim HY; Kim SY Korean J Pediatr 2018[Feb]; 61 (2): 37-42 PMID29563942show ga Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating disorder that progressively damages systemic organs, resulting in stroke, end-stage renal disease, and death. The traditional treatment for aHUS is mainly plasmapheresis or plasma infusion; however, many children with aHUS will progress to chronic kidney disease despite plasma therapy. Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Currently, several guidelines for aHUS, including the Korean guideline, recommend eculizumab as the first-line therapy in children with aHUS. Moreover, life-long eculizumab therapy is generally recommended. Further studies on discontinuation of eculizumab are needed. äAtypical hemolytic uremic syndrome and eculizumab therapy in children (epmc).pdf DeepDyve Pubget Overpricing